Adjuvant nivolumab monotherapy vs placebo for localized renal cell carcinoma at high risk of relapse after nephrectomy: Results from Part B of the randomized, phase 3 CheckMate 914 trial.

被引:5
作者
Motzer, Robert J.
Bex, Axel
Russo, Paul
Tomita, Yoshihiko
Cutuli, Hernan
Rojas, Carlos
Gross-Goupil, Marine
Schinzari, Giovanni
Melichar, Bohuslav
Barthelemy, Philippe
Garcia, Abraham Ruiz
Sosman, Jeffrey A.
Grimm, Marc-Oliver
Goh, Jeffrey C.
Suarez, Cristina
Kollmannsberger, Christian K.
Simsek, Burcin
Spiridigliozzi, Julia
Lee, Chung-Wei
Grunwald, Viktor
机构
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Netherlands Canc Inst, Amsterdam, Netherlands
[3] Niigata Univ, Grad Sch Med & Dent Sci, Niigata, Japan
[4] Hosp Sirio Libanes, Buenos Aires, DF, Argentina
[5] Bradford Hill, Santiago, Chile
[6] Ctr Hosp Univ, Bordeaux, France
[7] Fdn Policlin Univ Agostino Gemelli IRCCS, Rome, Italy
[8] Palacky Univ, Med Sch, Olomouc, Czech Republic
[9] Teaching Hosp, Olomouc, Czech Republic
[10] Inst Cancerol Strasbourg Europe, Strasbourg, France
[11] Hosp 1ro Octubre, Mexico City, DF, Mexico
[12] Northwestern Univ, Med Ctr, Chicago, IL USA
[13] Jena Univ Hosp, Jena, Germany
[14] ICON Res, South Brisbane, Qld, Australia
[15] Hosp Univ Vall dHebron, Vall dHebron Barcelona Hosp Campus, Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[16] Vancouver Canc Ctr, BC Canc, Vancouver, BC, Canada
[17] Bristol Myers Squibb, Princeton, NJ USA
[18] Univ Hosp Essen, West German Canc Ctr Essen, Clin Internal Med Tumor Res, Essen, Germany
[19] Univ Hosp Essen, West German Canc Ctr Essen, Clin Urol, Essen, Germany
关键词
613-225-313; 283-424-3231; 261-566-9263; 613-135-2370-7650-2454; 613-4678-146-485-2759; 613-135-2370-7650-2700; 281-318-5353-2387; 8; 7; 5; 3; 2; 14; 47; 242; 12; 1; 38092-20390;
D O I
10.1200/JCO.2024.42.4_suppl.LBA358
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:LBA358 / LBA358
页数:1
相关论文
empty
未找到相关数据